<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957577</url>
  </required_header>
  <id_info>
    <org_study_id>208636</org_study_id>
    <nct_id>NCT03957577</nct_id>
  </id_info>
  <brief_title>Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan</brief_title>
  <official_title>A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, epidemiological, cohort study is to evaluate the lung&#xD;
      microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese&#xD;
      participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with first evaluable moderate or severe AECOPD that have infectious or non-infectious etiology</measure>
    <time_frame>Up to Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiome composition of sputum in stable-state COPD as measured by bacterial ribosomal ribonucleic acid (rRNA) sequencing</measure>
    <time_frame>Baseline (Screening visit or Month 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause moderate and severe AECOPD per participants</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome composition of sputum in stable-state COPD as measured by bacterial rRNA sequencing</measure>
    <time_frame>Baseline (Screening visit or Month 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome composition of sputum during participant's first evaluable moderate or severe AECOPD</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria in stable state COPD as measured by bacterial culture or quantitative polymerase chain reaction (qPCR)</measure>
    <time_frame>Baseline (Screening visit or Month 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria during moderate or severe AECOPD as measured by bacterial culture or qPCR</measure>
    <time_frame>Baseline (Screening visit or Month 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of EXACT events per participant over the course of 12 months</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>An EXACT event is defined as an increase in EXACT score more than or equal to 12 points for 2 days or more than or equal to 9 points for 3 days, above the participant's mean Baseline score. Severity is indicated by the worst (i.e., highest) EXACT total score during the course of the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AECOPD events</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of AECOPD according to healthcare utilization</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of EXACT events according to EXACT total score</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of AECOPD</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of EXACT events</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CAT score between stable-state COPD and participants' first evaluable moderate or severe AECOPD</measure>
    <time_frame>Baseline (Screening visit or Month 0) and up to Month 12</time_frame>
    <description>The CAT is a 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Participants will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CAT score over the course of 1 year</measure>
    <time_frame>Baseline (Screening visit or Month 0) and up to Month 12</time_frame>
    <description>The CAT is a 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Participants will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in EXACT score</measure>
    <time_frame>Baseline(Screening visit or Month 0) and up to Month 12</time_frame>
    <description>EXACT is a validated, self-administered, 14-item daily diary that assesses 11 respiratory symptoms and 3 additional symptoms, which together characterize COPD exacerbations. The EXACT total score will range from 0 to 100, with higher scores indicating a more severe condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in E-RS COPD total and subscale scores between stable-state COPD and participants' first evaluable moderate or severe AECOPD</measure>
    <time_frame>Baseline (Screening visit or Month 0) and up to Month 12</time_frame>
    <description>The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in E-RS: COPD total and subscale scores over the course of 1 year</measure>
    <time_frame>Baseline (Screening visit or Month 0) and up to Month 12</time_frame>
    <description>The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Forced expiratory volume in 1 second (FEV1) between stable-state COPD, during participants' first evaluable moderate or severe AECOPD</measure>
    <time_frame>Baseline (Screening visit or Month 0) and up to month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of AECOPD related healthcare resource utilization per participant</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean rate of non-AECOPD related healthcare resource utilization per participant</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual rate of AECOPD related healthcare resource utilization per participant</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual rate of non-AECOPD related healthcare resource utilization per participant</measure>
    <time_frame>Up to Month 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants with COPD or Asthma-COPD overlap syndrome (ACOS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective observational cohort study</intervention_name>
    <description>Prospective observational cohort study</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll participants with a recorded clinical diagnosis of COPD, ACOS or&#xD;
        chronic bronchitis (CB), who have airflow limitation indicative of COPD according to Global&#xD;
        Initiative for Chronic Obstructive Lung Disease and a recent history of lower respiratory&#xD;
        tract infection (LRTI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be able and willing to comply with the requirements of the protocol.&#xD;
&#xD;
          -  Participant must be aged greater than or equal to (&gt;=)40 years to to less than or&#xD;
             equal to (&lt;=)80 years at the time of signing the informed consent form (ICF).&#xD;
&#xD;
          -  Participants must have a record of a clinical diagnosis of COPD, ACOS or CB.&#xD;
&#xD;
          -  Participants must have moderate to severe airflow limitation based on spirometry: FEV1&#xD;
             percent predicted normal &gt;=30 to &lt;=80 percent (%) and post-bronchodilator FEV1/forced&#xD;
             vital capacity (FVC) ratio &lt;0.7.&#xD;
&#xD;
          -  Participants must be symptomatic at Screening, defined as having a CAT score &gt;=10.&#xD;
&#xD;
          -  Participants must have a documented history of at least 1 LRTI treated with&#xD;
             antibiotics and/or oral/systemic corticosteroids.&#xD;
&#xD;
          -  Participants must be current or former tobacco (cigarette) smokers with a smoking&#xD;
             history of &gt;=10 pack-years.&#xD;
&#xD;
          -  Participants may be male or female. For female participants: A female participant is&#xD;
             eligible to participate if she is not pregnant or breastfeeding. Women of&#xD;
             non-childbearing potential can also participate. A woman of childbearing potential&#xD;
             must have had a highly sensitive negative urine pregnancy test.&#xD;
&#xD;
          -  Participants should be able to provide a spontaneous or induced sputum sample of &gt;=0.2&#xD;
             grams (g) at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with a diagnosed respiratory disorder other than COPD, ACOS or CB.&#xD;
&#xD;
          -  Participants with a diagnosis of alpha-1 antitrypsin deficiency as the underlying&#xD;
             cause of COPD.&#xD;
&#xD;
          -  Participants who have received antibiotics within 1 month of Screening or have&#xD;
             received antibiotics for more than 30 days within 90 days prior to Screening; Except&#xD;
             for those who have received and are currently receiving long-term treatment with&#xD;
             low-dose macrolide: erythromycin &lt;=600 milligrams (mg) per (/) day or clarithromycin&#xD;
             &lt;=200 mg/day.&#xD;
&#xD;
          -  Participants who have received systemic corticosteroids&#xD;
             (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days&#xD;
             prior to giving informed consent.&#xD;
&#xD;
          -  Participants who are unable to use or to comply with daily completion of the eDiary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ehime</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>859-0497</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niigata</city>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma-COPD overlap syndrome</keyword>
  <keyword>Acute exacerbations of chronic obstructive pulmonary disease</keyword>
  <keyword>Acute Exacerbation and Respiratory Infections in COPD-Japan</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Quantitative polymerase chain reaction (qPCR)</keyword>
  <keyword>16S ribosomal Ribonucleic acid (16S rRNA)</keyword>
  <keyword>Metagenomic analysis</keyword>
  <keyword>Sputum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

